CannPal Animal Therapeutics Limited (ASX: CP1), a pharmaceutical company focused on products for veterinary therapeutics derived from cannabis. CannPal is developing and researching therapeutics for veterinarians derived from cannabinoids for the treatment of animals.
Dr Margaret Curtis, Head of Research and Development at CannPal, presented much-awaited results for clinical trials using drug CPAT-01 at the 2019 AVA (Australian Veterinary Association). CannPal also filed further provisional patent application relating to CPAT-01 after results from ongoing research.
Receptors and endogenous cannabinoids (CBs) form the Endocannabinoid system (ECS) which affects cognitive, physiological and metabolic functions in animals. ECS is a therapeutic target for medical cannabis. Cannabis comprises cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD). The pet medicine consisting of THC and CBD used for RCT (Randomized controlled trial) is grown in greenhouses and produced in Canada. The tests are designed to study the influence of THC and CBD on pain and inflammatory pathways associated with the endocannabinoid system (ECS).
The company conducted a randomised three group parallel dose-evaluation study including three samples of respondents with four beagle dogs each in group 1 and group 2 and 3 beagle dogs in group 3, taking total 11 healthy male beagle dogs into the consideration. The composition of medicines –
|3||placebo containing no CBs; MCT Oil only|
After 40 to 90 mins of treatment, both groups remained at the time of peak concentration (Tmax) for both CBD and THC.
Mean THC/CBD peak concentration in groups (Cmax) –
|1||46.6 ng/mL||13.1 ng/mL|
|2||38.8 ng/mL||37.8 ng/mL|
The results for tests indicated significant differences recorded within 0-24 hours, the effects of dosage suggest that medicine have the potential to control pain and inflammation in dogs and support the Endocannabinoid system (ECS) in animals. Research also concluded, good numbers of pain and inflammatory genes and cytokines that were modified by treatment in healthy dogs.
- Restricted maximum likelihood models were used to evaluate the differences between groups.
- CB2 cannabinoid receptor 2 was impacted by treatment when the dogs treated with cannabinoids (THC and CBD). Receptors found in ECS have a wide variety of tissues including in the immune system, the central and peripheral nervous system, the gut and reproductive organs. They play an essential role in pain and inflammatory signalling and responses.
- (p<0.1) – Significant changes in biomarkers known for the anti-inflammatory process were in seen group 1 and 2 meanwhile no differences observed in group 3.
- Interleukin 15 is another pro-inflammatory cytokine found in group 2
- GM-CSF, a pro-inflammatory cytokine was reduced by treatment. It is consistent with the effects seen in humans treated with THC and CBD (Zgair et al. 2017)
The company is working on the extensive pharmacokinetic study, toxicology studies and further future work including dose determination study in client-owned dogs and safety study in healthy beagle dogs.
CP1 last traded at $0.155, down 3.125% on 7 May 2019. Over the past 12 months, the stock has gone down by 27.27%. The 52-week high and low of the stock stands at $0.240 and $0.105, respectively.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is sponsored but NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. We are neither licensed nor qualified to provide investment advice through this platform.